CN113293148B - 一种h基因替换的嵌合麻疹减毒株的构建 - Google Patents

一种h基因替换的嵌合麻疹减毒株的构建 Download PDF

Info

Publication number
CN113293148B
CN113293148B CN202110262340.1A CN202110262340A CN113293148B CN 113293148 B CN113293148 B CN 113293148B CN 202110262340 A CN202110262340 A CN 202110262340A CN 113293148 B CN113293148 B CN 113293148B
Authority
CN
China
Prior art keywords
virus
measles virus
leu
strain
measles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110262340.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN113293148A (zh
Inventor
安祺
朱凤才
田大勇
解丽霞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Saierfusen Biotechnology Co ltd
Shanghai Qingsai Biotechnology Co ltd
Original Assignee
Beijing Saierfusen Biotechnology Co ltd
Shanghai Qingsai Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Saierfusen Biotechnology Co ltd, Shanghai Qingsai Biotechnology Co ltd filed Critical Beijing Saierfusen Biotechnology Co ltd
Priority to CN202110262340.1A priority Critical patent/CN113293148B/zh
Publication of CN113293148A publication Critical patent/CN113293148A/zh
Priority to PCT/CN2022/079777 priority patent/WO2022188784A1/fr
Application granted granted Critical
Publication of CN113293148B publication Critical patent/CN113293148B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18423—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202110262340.1A 2021-03-10 2021-03-10 一种h基因替换的嵌合麻疹减毒株的构建 Active CN113293148B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202110262340.1A CN113293148B (zh) 2021-03-10 2021-03-10 一种h基因替换的嵌合麻疹减毒株的构建
PCT/CN2022/079777 WO2022188784A1 (fr) 2021-03-10 2022-03-08 Construction d'une souche chimérique atténuée de rougeole à remplacement du gène h

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110262340.1A CN113293148B (zh) 2021-03-10 2021-03-10 一种h基因替换的嵌合麻疹减毒株的构建

Publications (2)

Publication Number Publication Date
CN113293148A CN113293148A (zh) 2021-08-24
CN113293148B true CN113293148B (zh) 2022-10-25

Family

ID=77319129

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110262340.1A Active CN113293148B (zh) 2021-03-10 2021-03-10 一种h基因替换的嵌合麻疹减毒株的构建

Country Status (2)

Country Link
CN (1) CN113293148B (fr)
WO (1) WO2022188784A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113293148B (zh) * 2021-03-10 2022-10-25 上海青赛生物科技有限公司 一种h基因替换的嵌合麻疹减毒株的构建
CN113999824B (zh) * 2021-12-30 2022-11-11 北京赛尔富森生物科技有限公司 H1a基因型嵌合麻疹病毒减毒株和制备方法及用途
CN113999823B (zh) * 2021-12-30 2022-04-26 北京赛尔富森生物科技有限公司 D8基因型嵌合麻疹病毒减毒株和制备方法及用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60233038D1 (de) * 2002-06-20 2009-09-03 Pasteur Institut Infektiöse cDNA eines zugelassenen Impfstammes des Masern Virus. Verwendung in immunogenen Zusammensetzungen
EP2303322A1 (fr) * 2008-06-20 2011-04-06 Bavarian Nordic A/S Vaccin anti-rougeole à base du virus de la vaccine modifié recombinant
CN101323857A (zh) * 2008-08-01 2008-12-17 中国疾病预防控制中心病毒病预防控制所 改造型麻疹病毒全基因cDNA克隆及感染性病毒的制备
EP2420242A1 (fr) * 2010-08-20 2012-02-22 Lauer, Ulrich M. Virus de la rougeole oncolytique
JP5917626B2 (ja) * 2014-07-28 2016-05-18 トレムアールエックス， インコーポレイテッド 機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種
CN111100845B (zh) * 2018-10-25 2023-04-11 浙江大学 一种重组麻疹病毒及其制备方法和应用
CN111019910B (zh) * 2019-11-04 2022-03-15 上海青赛生物科技有限公司 F基因型腮腺炎病毒减毒株及构建方法和应用
CN113293148B (zh) * 2021-03-10 2022-10-25 上海青赛生物科技有限公司 一种h基因替换的嵌合麻疹减毒株的构建
CN113999824B (zh) * 2021-12-30 2022-11-11 北京赛尔富森生物科技有限公司 H1a基因型嵌合麻疹病毒减毒株和制备方法及用途

Also Published As

Publication number Publication date
CN113293148A (zh) 2021-08-24
WO2022188784A1 (fr) 2022-09-15

Similar Documents

Publication Publication Date Title
CN113293148B (zh) 一种h基因替换的嵌合麻疹减毒株的构建
CN113293145B (zh) 一种麻疹病毒活载体新冠疫苗
CN113293149B (zh) 一种f基因替换的嵌合麻疹减毒株的构建
CN111019910B (zh) F基因型腮腺炎病毒减毒株及构建方法和应用
CN113201507B (zh) 一种重组的伪狂犬病病毒及其疫苗组合物
JP2013099357A (ja) 弱毒化ペスチウイルス
CN115998856A (zh) 一种新冠流感免疫原性组合物及其制备方法和应用
WO2010088552A1 (fr) Compositions immunogènes, vaccins et diagnostics à base de virus de la maladie de carré circulant chez les chiens nord-américains
CN108728490A (zh) 一种基于杆状病毒载体的鲤疱疹病毒ii型dna疫苗及其构建方法与应用
CN110256539A (zh) O型口蹄疫病毒新型基因工程亚单位疫苗
CN109321535A (zh) 一种热稳定的新城疫病毒弱毒疫苗候选株
CN109321534A (zh) 一种重组基因viii型新城疫病毒弱毒株
CN116102660B (zh) 一种猪细小病毒基因工程表位疫苗及其制备方法
CN111647087B (zh) 一种嵌合病毒样颗粒疫苗及其制备方法和应用
CN113293144B (zh) 一种重组f基因型腮腺炎病毒活载体麻疹疫苗
US10894081B2 (en) Recombinant bivalent inactivated vaccine against foot-and-mouth disease virus, preparation method and use thereof
JP6280635B2 (ja) 安定化ｆｍｄｖキャプシド
CN116376850A (zh) B3基因型嵌合麻疹病毒减毒株和制备方法及用途
CN112111467B (zh) 一种基因vii型新城疫标记疫苗株及其制备方法与应用
CN111729078B (zh) 鸡传染性贫血病毒基因工程疫苗
CN111533811B (zh) 禽脑脊髓炎病毒新型基因工程疫苗
CN111349621A (zh) 一种重组杆状病毒及其在制备新城疫病毒样颗粒中的应用
CN116785422B (zh) 含有新型冠状病毒联合抗原的麻疹减毒疫苗及其拯救方法
KR102542601B1 (ko) 신규한 돼지 유행성 설사병 바이러스 및 이의 용도
KR102365039B1 (ko) 부유세포 배양에 적응된 A/ASIA/Sea-97 유전형 구제역 바이러스 백신주 및 이의 제조방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: 201507 No. 1136, langong Road, Jinshan Industrial Zone, Jinshan District, Shanghai

Patentee after: Shanghai Qingsai Biotechnology Co.,Ltd.

Patentee after: Beijing saierfusen Biotechnology Co.,Ltd.

Address before: 201507 No. 1136, langong Road, Jinshan Industrial Zone, Jinshan District, Shanghai

Patentee before: Shanghai Qingsai Biotechnology Co.,Ltd.

Patentee before: Beijing saierfusen Biotechnology Co.,Ltd.

PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Construction of a chimeric measles attenuated strain with H gene replacement

Effective date of registration: 20230718

Granted publication date: 20221025

Pledgee: China Minsheng Banking Corp Shanghai branch

Pledgor: Shanghai Qingsai Biotechnology Co.,Ltd.|Beijing saierfusen Biotechnology Co.,Ltd.

Registration number: Y2023310000382